Minoxidil to Minoxidil Sulfate: The Enzyme Conversion That Makes It Work

Minoxidil is not active as applied. A scalp enzyme converts it to minoxidil sulfate — the compound that actually opens potassium channels. That conversion step is what makes some people respond brilliantly and others barely at all.

The prodrug concept is fundamental to understanding why minoxidil behaves the way it does — why some people respond dramatically, why others respond minimally, and why the conversion enzyme is the rate-limiting step that determines nearly everything about individual outcomes.

Minoxidil as a prodrug

A prodrug is a compound that is pharmacologically inactive as administered and must be converted by metabolic processes to its active form. Minoxidil is a prodrug: the compound applied to the scalp or swallowed in a tablet does not open potassium channels or dilate blood vessels in its original form. It must first be sulfated by the enzyme sulfotransferase (specifically SULT1A1) to become minoxidil sulfate, which is the pharmacologically active compound.

This is not a trivial distinction. It means that the effectiveness of topical minoxidil depends not only on how much minoxidil reaches the scalp but on how much of that minoxidil gets converted to the active sulfate form by the enzyme present in the follicle.

Where the conversion happens

Sulfotransferase activity relevant to minoxidil conversion has been identified in multiple tissues, but the tissue that matters for hair is the outer root sheath (ORS) of the hair follicle. ORS cells express SULT1A1 and perform the sulfation step locally. This means the conversion from prodrug to active metabolite happens directly in the follicle itself — the right place, with obvious implications for how directly effective the conversion is for hair growth.

Why conversion activity varies between individuals

SULT1A1 enzyme activity varies substantially between individuals based on genetic factors — specifically, polymorphisms in the SULT1A1 gene that affect enzyme expression and activity. People with high SULT1A1 activity convert more minoxidil to the active sulfate at the follicle; people with low activity convert less.

This genetic variation in enzyme activity is the primary biological explanation for the wide range in individual minoxidil response. It is not primarily about scalp penetration, product quality, or application technique — it is about how efficiently each individual's follicle cells perform the conversion that makes the compound active.

Oral minoxidil and the conversion step

Oral minoxidil is also a prodrug and also requires sulfation to become active. The systemic absorption from oral dosing means the compound distributes throughout the body, and sulfation occurs in multiple tissues. The sulfotransferase activity that matters for hair, however, is still primarily at the follicle level. Oral dosing does not bypass the enzyme step — it just delivers more prodrug to the follicle than topical application in some individuals with absorption variability.

Some non-responders to topical minoxidil respond to oral, suggesting that the topical route may have absorption limitations in some scalp types that oral dosing overcomes. But if the fundamental issue is very low SULT1A1 activity at the follicle, oral dosing may not fully resolve the non-response either.